切迫性尿失禁を伴う女性過活動膀胱患者に対する塩酸プロピベリンによる症状・QOL改善効果および安全性の検討

Abstract

58例(平均68歳)の患者を対象として塩酸プロピベリン経口投与による治療を行い, 治療前, 治療4週後および8週後において, 国際尿失禁会議質問票(ICIQ-SF)・キング健康調査票(KHQ)・排尿日誌および尿意切迫感に関する問診票により症状・QOLスコア, 自覚症状の改善を評価した。1日の平均排尿回数, 平均失禁回数, 平均尿意切迫感回数および尿意切迫感程度はいずれも治療前と比較して治療4週後に有意に減少し8週後も効果は持続した。また, ICIQ-SF総スコアおよびKHQスコアも治療後有意な改善を認めた。安全性評価症例42例中10例(23.8%)に有害事象を認めたが, いずれも重篤ではなく投与中止あるいは減量した例はなかった。

The present study was prospectively conducted for female patients with wet overactive bladder to assess the efficacy of propiverine hydrochloride in improving their symptoms and quality of life (QOL). Propiverine hydrochloride was administered orally to 58 patients for 8 weeks. Prior to administration and at 4 and 8 weeks after administration, symptoms and QOL were assessed by the micturition diary, the International Consultation on Incontinence-Short Form (ICIQ-SF), and the King's Health Questionnaire (KHQ). After administration, numbers of daily micturitions, incontinence episodes, urgency episodes and severity of urgency which were assessed based on the micturition diary and urgency scale questionnaire showed significant improvement when compared to baseline values. Furthermore, both ICIQ-SF and KHQ scores improved significantly after administration. The incidence of adverse events was 23.8% and none were serious. Propiverine hydrochloride was shown to contribute not only to the improvement of symptoms in female patients with wet overactive bladder but also to their QOL.